Illinois Municipal Retirement Fund Has $3.19 Million Holdings in Axon Enterprise, Inc $AXON

Illinois Municipal Retirement Fund lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 66.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,854 shares of the biotechnology company’s stock after selling 7,804 shares during the period. Illinois Municipal Retirement Fund’s holdings in Axon Enterprise were worth $3,191,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Axon Enterprise by 15.9% during the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after buying an additional 175,890 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Axon Enterprise by 1.2% during the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after buying an additional 8,794 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after acquiring an additional 611,418 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Down 0.5%

AXON opened at $569.51 on Thursday. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91. The company has a fifty day moving average of $709.82 and a 200-day moving average of $735.72. The stock has a market cap of $44.94 billion, a PE ratio of 140.62, a price-to-earnings-growth ratio of 29.49 and a beta of 1.45. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. During the same quarter in the previous year, the company posted $1.45 earnings per share. Axon Enterprise’s quarterly revenue was up 30.6% on a year-over-year basis. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of research reports. Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. UBS Group reduced their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Piper Sandler dropped their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a report on Tuesday, August 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research report on Wednesday, September 24th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $810.71.

Insiders Place Their Bets

In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of Axon Enterprise stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the transaction, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. The trade was a 0.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president directly owned 238,379 shares of the company’s stock, valued at $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 52,041 shares of company stock worth $36,794,077 in the last 90 days. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.